| Mission Statement: THERAmolecular is a small biotech research startup company
dedicated to the discovery, design of safe and effective
therapeutics for a range of human and animal diseases. We pursue this
goal through the application of state-of-the-art computational
chemistry methods and strategies, including advanced bioinformatics, cheminformatics
and machine learning approaches. |
| Leveraging Technological Advancements: No longer is world-class drug discovery confined solely
to the realm of deep-pocket pharmaceutical giants. Rapid advances in technology
have democratized, diversified and empowered individuals and micro-companies (like THERAmolecular) to catalyze and accelerate early-stage discovery
of novel drugs that have a very reasonable chance of entering clinical trial. These technological
advances include artificial intelligence and machine learning, faster
computers, cloud computing, rapidly evolving drug-design software and
improved understanding of chemistry and molecular physics at the
quantum level. We do not view our role as developers of these
technologies; rather, we evaluate new software algorithms and
applications for speed, accuracy, reliability, cost and so forth. Then
we quickly adopt and apply the very best breakthrough technologies in
our new drug discovery programs. |
 Our Business Model: At THERAmolecular we are caring and skilled
research scientists dedicated to the discovery and design of safe and
effective therapeutics that can make the world a better place. We are
driven by a passion for the basic scientific work we undertake and a strong desire to help
humanity overcome health challenges. Unlike some investor-driven drug
companies that are motivated solely by
the prospect of immediate
financial windfalls, we reinvest our revenue back
into our drug innovation pipeline. This is not to say we do not
appreciate the value of drug IP ownership and understand the necessity
for it in a front-loaded capital-intensive endeavor, such as drug
discovery. Indeed, we ourselves are a for-profit company that can only
survive if large biopharma companies acquire our drug IP for
subsequent lab testing/analysis, optimization, animal and human trials,
and eventual FDA-approval, all of which are extremely expensive.
Rather, our business model attempts to highlight a distinction between
the fundamental science of early-stage drug-discovery (including target identification, molecular design, synthetic routes, etc.) from downstream commercially-oriented
aspects of drug development and deployment, including animal model trials, human clinical trials,
FDA approval and marketing phases. |
| Once a new drug leaves THERAmolecular and is acquired by another
company or agency, THERAmolecular steps aside and no longer is involved
in the commercial fate of that drug. We are grateful to have played our
small part in ushering in a virgin drug to the world. At the same time,
we hope that its new owner will unleash its full potential in the
commercial sector so the drug can be made available at a fair price to
all of those in need. |
